Determination of Regulatory Review Period for Purposes of Patent Extension; Lipitor

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for Lipitor, a human drug product, and is publishing this notice as required by law. The determination was made due to a submission to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of the patent.